At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 94 enrolled
Drug / intervention
dasatinib +1 moredrug
Likely dose
dasatinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating dasatinib for Prostate Cancer. Completed, enrolled 94 participants across 11 sites in 3 countries.
Detailed Summary
The purpose of this study is to learn if men with metastatic prostate cancer and rising Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing androgen deprivation with Luteinizing Hormone Releasing Hormone (LHRH) treatment, respond to dasatinib. The safety of this treatment will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesFrance, Italy, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartJan 2007
Primary CompletionDec 2008
Study CompletionOct 2010
TodayJul 2026
First PostedOct 9, 2006
Enrollment StartJan 1, 2007
Primary CompletionDec 1, 2008
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.7 years ago
Interventions
dasatinibdrug
Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
dasatinibdrug
Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression